Don’t let them threaten your drug development plans
Advancing your drug or vaccine candidate from late-stage discovery into the clinic is one of the most critical steps in development. To maximize your chances of success, it is essential to de-risk your drug candidates as early as possible.
This seminar will provide insights and solutions how to de-risk your development and to accelerate your path to FIH (First-in-Human) clinical studies.
Learn about how in silico and in vitro protein design and optimization tools can help you to identify and mitigate manufacturing, development and immunogenicity liabilities and to improve the quality and safety of your therapeutic proteins
Date: Wednesday 1st of June 2022
Time: 9:00 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
|9:00||Networking, registration and light breakfast|
David Munis Zepernick, Head of Member Engagement and Communication, Medicon Valley Alliance
Mattias Nyström, Account Manager, Lonza Biologics
|9:35||Developability and Immunosafety : Don’t let them threaten your drug development plans|
Noel Smith, PhD, Head of Immunology, Early Development Services, Lonza
|11:00||End of Good Morning Meeting|
|Noel Smith, PhD, Head of Immunology, Early Development Services, Lonza|
Noel completed his PhD and post-doctoral studies at the University of Cambridge in the field of metabolic disease.
He joined Lonza in 2009 and was involved in the setup of the human primary cell-based assay platform and now heads the Immunology group which develops assays to screen products for immunogenicity and immunotoxicity risk.
The Lonza Cambridge site focuses on supporting the development of new biotherapeutic proteins and vaccines with a particular focus on immunosafety, manufacturability and protein expression.
|Organized by||In collaboration with|